How much atrial fibrillation is too much?  The net clinical benefit of anticoagulation therapy in atrial fibrillation patients with an intermediate CHA2DS2-VASc Score by Stovall, Rebekah et al.
James Madison University 
JMU Scholarly Commons 
Physician Assistant Capstones The Graduate School 
Spring 5-4-2017 
How much atrial fibrillation is too much? The net clinical benefit 
of anticoagulation therapy in atrial fibrillation patients with an 
intermediate CHA2DS2-VASc Score 
Rebekah Stovall 
James Madison University 
Ashley Carter 
James Madison University 
Lynsey Deudne 
James Madison University 
Follow this and additional works at: https://commons.lib.jmu.edu/pacapstones 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Carter A, Deudne L, Stovall R. How much atrial fibrillation is too much? The net clinical benefit of 
anticoagulation therapy in atrial fibrillation patients with an intermediate CHA2DS2-VASc score. JMU 
Scholarly Commons Physician Assistant Capstones. http://commons.lib.jmu.edu/pacapstones/22. 
Published May 16, 2017. 
This Presentation is brought to you for free and open access by the The Graduate School at JMU Scholarly 
Commons. It has been accepted for inclusion in Physician Assistant Capstones by an authorized administrator of 
JMU Scholarly Commons. For more information, please contact dc_admin@jmu.edu. 
How	  Much	  Atrial	  Fibrillation	  Is	  Too	  Much?
The	  Net	  Clinical	  Benefit	  of	  Oral	  Anticoagulation	  Therapy	  in	  Atrial	  Fibrillation	  Patients	  With	  an	  Intermediate	  CHA2DS2-­‐VASc	  Score
Ashley	  Carter,	  PA-­‐S,	  Lynsey Deudne,	  PA-­‐S,	  Rebekah	  Stovall,	  PA-­‐S
James	  Madison	  University,	  Harrisonburg	  ,VA





§ Atrial	  fibrillation	  (AF)	  is	  the	  most	  prevalent	  sustained	  cardiac	  
arrhythmia,	  affecting	  33.5	  million	  people	  worldwide
§ Arterial	  thromboembolism,	  particularly	  ischemic	  stroke	  (IS),	  is	  a	  
significant	  complication	  of	  AF
§ The	  most	  widely	  recommended	  tool	  used	  to	  evaluate	  AF	  patient’s	  risk	  
of	  IS	  is	  the	  CHA2DS2-­‐VASc	  score
§ It	  assigns	  a	  numerical	  value	  to	  pre-­‐determined	  IS	  risk	  factors	  and	  allows	  
an	  overall	  estimation	  of	  the	  patient’s	  risk
§ Various	  organizations	  provide	  different	  recommendations	  for	  oral	  
anticoagulation	  (OAC)	  therapy,	  making	  it	  difficult	  for	  providers	  to	  
develop	  treatment	  plans	  for	  this	  patient	  population	  (see	  Table	  1)
The	  purpose	  of	  this	  review	  is	  to	  evaluate	  the	  net	  clinical	  benefit	  (NCB)	  
when	  comparing	  IS	  risk	  to	  that	  of	  hemorrhagic	  complications	  when	  
prescribing	  OAC	  therapy	  to	  patients	  who	  have	  at	  least	  1	  non-­‐gender	  
(NGR)	  risk	  factor	  for	  IS	  or	  an	  intermediate	  CHA2DS2-­‐VASc score.
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CONCLUSIONS




Should	  Atrial	  Fibrillation	  Patients	  With	  1	  Additional	  Risk	  Factor	  of	  the	  CHA2DS2-­‐
VASc	  Score	  (Beyond	  Sex)	  Receive	  Oral	  Anticoagulation?
Objective: To	  determine	  whether	  the	  presence	  of	  a	  single	  NGR	  risk	  factor	  increases	  the	  
annual	  rate	  of	  IS	  in	  Taiwanese	  AF	  patients	  aged	  20	  years	  and	  older.
Study	  Design:	  Retrospective	  cohort using	  data	  from	  the	  National	  Health	  Insurance	  Research	  
Database	  (NHIRD)	  regarding	  AF	  patients.	  They	  were	  assigned	  a	  CHA2DS2-­‐VASc	  score	  based	  on	  
their	  risk	  factors	  and	  outcome	  of	  IS	  was	  evaluated.	  
Results:	  The	  average	  annual	  IS	  rate	  for	  males	  with	  a	  CHA2DS2-­‐VASc	  score	  of	  1	  was	  2.75%	  	  and	  
for	  females	  with	  a	  CHA2DS2-­‐VASc	  of	  2	  was	  2.55%.
Study	  Critique:	  It’s	  the	  first	  population	  based	  investigation	  addressing	  our	  clinical	  question	  
setting	  the	  stage	  for	  research	  to	  come.	  However	  it	  could	  be	  undermining	  the	  annual	  stroke	  
rate	  due	  to	  inclusion	  of	  patients	  who	  could	  have	  been	  prescribed	  antithrombotic	  therapy	  90	  
days	  after	  the	  diagnosis	  of	  AF.
Should	  Atrial	  Fibrillation	  Patients	  With	  Only	  1	  Nongender-­‐Related	  CHA2DS2-­‐VASc	  
Risk	  Factor	  be	  Anticoagulated?
Objective: To	  measure	  whether	  a	  single	  NGR	  CHA2DS2-­‐VASc risk	  factor	  confers	  a	  significant	  
risk	  of	  IS	  and	  if	  the	  use	  of	  OAC	  can	  reduce	  IS	  risk	  with	  minimal	  hemorrhagic	  complications.	  
Study	  Design:	  	  Retrospective	  community	  cohort	  investigating	  adverse	  outcomes	  of	  OAC	  use	  
in	  nonvalvular AF	  patients	  with	  just	  one	  NGR	  risk	  factor	  in	  accordance	  with	  CHA2DS2-­‐VASc risk	  
assessment.	  	  Adverse	  outcomes	  included	  rates	  of	  IS,	  intracranial	  hemorrhage,	  major	  
extracranial bleeding,	  and	  myocardial	  infarction.	  Net	  clinical	  benefit	  was	  calculated	  using	  2	  
methodologies: Singer	  et	  al	  and	  Connolly	  et	  al	  formula.
Results: A	  positive	  net	  clinical	  benefit	  was	  measured	  in	  favor	  of	  vitamin	  K	  antagonists	  when	  
comparing	  the	  benefit	  of	  IS	  reduction	  against	  the	  increased	  risk	  of	  ICH	  in	  patients	  with	  1	  NGR	  
risk	  factor	  and	  nonvalvular AF.	  This	  was	  consistent	  across	  both	  the	  Singer	  and	  Connolly	  
methodologies.	  
Critique:	  Real	  world	  registry	  data	  from	  a	  large	  cohort	  of	  consecutive	  patients	  recruited	  and	  
data	  is	  complementary	  to	  data	  reported	  in	  randomized	  clinical	  trials.	  However,	  patients	  are	  at	  
risk	  for	  changes	  in	  treatment	  during	  follow-­‐up	  	  which	  was	  impossible	  to	  make	  adjustments	  for	  
in	  a	  multivariable	  analysis.
Ischemic	  Stroke	  Risk	  in	  Patients	  with	  Atrial	  Fibrillation	  and	  CHA2DS2-­‐VASc	  score	  of	  
1;	  Systematic	  Review	  and	  Meta-­‐analysis.
Objective:	  To	  reduce	  uncertainty	  about	  OAC	  therapy	  in	  patients	  with	  a	  CHA2DS2-­‐VASc score	  
of	  1	  by	  comparing	  annual	  IS	  rates	  in	  AF	  patients	  to	  pre-­‐determined	  OAC	  therapy	  thresholds.
Study	  Design:	  Systematic	  review	  and	  meta-­‐analysis
Results:	  Patients	  with	  a	  CHA2DS2-­‐VASc score	  of	  0	  do	  not	  meet	  the	  treatment	  threshold	  for	  
OAC	  therapy. Patients	  with	  a	  CHA2DS2-­‐VASc score	  of	  1	  meet	  the	  treatment	  threshold	  for	  
novel	  OAC	  therapy	  but	  not	  warfarin. Patients	  with	  a	  CHA2DS2-­‐VASc	  score	  of	  2	  meet	  the	  
treatment	  threshold	  for	  both	  novel	  OAC	  and	  warfarin.
Study	  Critique:	  Weaknesses	  of	  this	  meta-­‐analysis	  include	  wide	  confidence	  intervals,	  
significant	  heterogeneity,	  several	  types	  of	  bias,	  and	  a	  lack	  of	  discussion	  regarding	  the	  quality	  
of	  the	  included	  studies. Strengths	  of	  the	  study	  include	  its	  recent	  publication	  date,	  its	  large	  





Men No	  therapy Oral	  anticoagulation,	  aspirin,	  or	  no	  therapy Oral	  anticoagulation
Women N/A Oral	  anticoagulation,	  aspirin,	  or	  no	  therapy Oral	  anticoagulation
ESC	  and	  NICE
Men No	  therapy Oral	  anticoagulation Oral	  anticoagulation
Women N/A No	  therapy Oral	  anticoagulation
Key:	  ACC:	  American	  College	  of	  Cardiology,	  AHA:	  American	  Heart	  Association,	  ESC:	  European	  Society	  of	  Cardiology,	  HRS:	  Heart	  Rhythm	  
Society,	  NICE:	  National	  Institute	  for	  Health	  and	  Care	  Excellence
Based	  on	  our	  review	  of	  the	  current	  literature,	  we	  found	  that	  the	  
presence	  of	  even	  1	  NGR	  risk	  factor	  significantly	  increases	  a	  patient’s	  risk	  
of	  IS.	  Therefore,	  we	  agree	  with	  the	  European	  Society	  of	  Cardiology	  (ESC)	  
and	  the	  National	  Institute	  for	  Health	  and	  Care	  Excellence	  (NICE)	  
guidelines	  that	  support	  considering	  anticoagulation	  therapy	  in	  AF	  
patients	  with	  1	  NGR	  risk	  factor,	  and	  we	  suggest	  that	  the	  American	  
College	  of	  Cardiology,	  American	  Heart	  Association,	  and	  the	  Heart	  
Rhythm	  Society	  (ACC/AHA/HRS)	  guidelines	  follow	  suit.




Study	  1 Retrospective	  Cohort Taiwan 20,838	  patients
Recommend	  
anticoagulation	  
therapy	  in	  patients	  
with	  1	  or	  more	  NGR	  
risk	  factors	  for	  IS	  
(CHA2DS2-­‐VASc	  score	  
of	  1	  for	  males	  and	  2	  
for	  females)





Studies	  Included	  in	  the	  
Meta-­‐Analysis:
Banerjee	  et	  al:	  
Denmark
Chao	  et	  al:	  Taiwan
Friberg et	  al:	  Sweden
Hobbs	  et	  al:	  United	  
Kingdom
Huang	  et	  al:	  China
Komatsu	  et	  al:	  Japan
Larsen	  et	  al:	  Denmark
Lip	  et	  al:	  Multi-­‐Country
Siu	  et	  al:	  China
Suzuki	  et	  al:	  Japan
Studies	  Included	  in	  
the	  Meta-­‐Analysis:
Banerjee	  et	  al:	  
132,372
Chao	  et	  al:	  186,570
Friberg et	  al:	  182,678
Hobbs	  et	  al:	  665
Huang	  et	  al:	  548
Komatsu	  et	  al:	  332
Larsen	  et	  al:	  1,603
Lip	  et	  al:	  5,599
Siu	  et	  al:	  9,727
Suzuki	  et	  al:	  3,588
Recommend	  
considering	  OAC	  
therapy	  in	  patients	  
with	  a	  total	  CHA2DS2-­‐
VASc	  score	  of	  1	  or	  
higher	  for	  males	  and	  
females.
Table	  2:	  Study	  Characteristics	  
Figure	  1:	  PRISMA	  Article	  Selection	  Criteria	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